Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
2010-023097-40Phase 2Active
- Sponsor
- Pharnext
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) (4 arms), sponsored by Pharnext. Primary endpoint: Incidence of related adverse events with moderate or severe intensity. Started Oct 2010; status: active.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on 2010-023097-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023097-40.